Landos Biopharma, Inc , a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases.
infoLandos Biopharma is a micro cap stock with a total market cap of 11.56M.
infoThey trade on the NASDAQ and had their IPO 2 years and 6 months ago.
infoLandos Biopharma currently employs 22 people.
infoAs of Wednesday, Aug 23 2023, Landos Biopharma’s share price is $3.71.
News Relating to Landos Biopharma
GlobeNewsWire
Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference
Wednesday May 31 2023 at 16:15
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will participate at the Jefferies Healthcare Conference, to be held from June 7-9, 2023 in New York, NY.
PennyStocks
3 Top Biotech Penny Stocks Under $3 To Watch Right Now
Monday Dec 19 2022 at 13:00
Biotech penny stocks to watch right now. The post 3 Top Biotech Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
Wednesday May 11 2022 at 09:02
Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.
Seeking Alpha
Landos Biopharma, Inc.’s (LABP) CEO Tim Mayleben on Q3 2021 Results – Earnings Call Transcript
Monday Nov 15 2021 at 10:59
Landos Biopharma, Inc.’s (LABP) CEO Tim Mayleben on Q3 2021 Results – Earnings Call Transcript
Zacks Investment Research
Should You Buy Landos Biopharma (LABP) Ahead of Earnings?
Wednesday Nov 10 2021 at 09:57
Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GlobeNewsWire
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus
Monday Oct 11 2021 at 07:00
Phase 1 trial initiation expected before yearend with topline results in 1H 2022
GlobeNewsWire
Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor’s Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism
Wednesday Oct 06 2021 at 07:00
BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, today announced the publication of a peer-reviewed article titled “First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of the LANCL2 pathway in psoriasis” in Scientific Reports. The peer-reviewed publication demonstrates omilancor’s therapeutic efficacy in animal models of psoriasis.
GlobeNewsWire
Landos Biopharma to Participate in Two Upcoming Investor Conferences in September
Wednesday Sep 01 2021 at 07:00
BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos will participate in two upcoming virtual investor conferences in September.
GlobeNewsWire
Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine
Thursday Aug 26 2021 at 07:00
BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that it has entered into a research collaboration with Peter Calabresi, M.D., Director of the Multiple Sclerosis Center and Professor of Neurology at Johns Hopkins University (JHU) School of Medicine. This research funded by the National Institutes of Health (NIH) will focus on further validating the NLRX1 immunometabolic pathway in Multiple Sclerosis (MS).
GlobeNewsWire
Landos Biopharma to Participate in Upcoming Investor Events
Thursday Aug 05 2021 at 07:00
BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos and additional management team members will participate in the following investor events in August.
GlobeNewsWire
Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference
Monday Jun 14 2021 at 17:08
BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Raymond James Virtual Human Health Innovation Conference on Monday, June 21, 2021 at 2:00 PM EDT.
GlobeNewsWire
Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients
Monday Jun 14 2021 at 07:00
The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor
GlobeNewsWire
Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference
Tuesday May 25 2021 at 07:00
BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:00 AM EDT.
Seeking Alpha
Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal
Sunday May 23 2021 at 23:15
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreement.
GlobeNewsWire
Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors
Wednesday May 19 2021 at 07:00
BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board of Directors. Mr. Mayleben joins Landos with more than 20 years of executive experience leading development activities as well as successfully spearheading clinical and business strategies within the life sciences industry.
Benzinga
Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China
Monday May 17 2021 at 09:29
Landos Biopharma Inc (NASDAQ: LABP) and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainland China, Hong Kong, Taiwan, and Macau) and select Asian markets. Omilancor is a novel, oral, gut-restricted LANCL2 agonist in development for the treatment of ulcerative colitis (UC), Crohn’s disease (CD), and Eosinophilic Esophagitis (EoE).
GlobeNewsWire
Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates
Monday May 17 2021 at 07:15
Completed initial public offering of common stock, raising approximately $100 million in gross proceeds
GlobeNewsWire
Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American Association of Immunologists (AAI) Annual Meeting
Monday Apr 26 2021 at 07:00
BLACKSBURG, Va., April 26, 2021 (GLOBE NEWSWIRE) — Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that two late-breaking abstracts on preclinical data of omilancor in psoriasis and proof-of concept preclinical data of PX-69 in rheumatoid arthritis will be presented at the upcoming American Association of Immunologists (AAI) Annual Meeting 2021. The meeting will be held virtually from May 10-15, 2021.
Benzinga
Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation
Tuesday Apr 06 2021 at 09:53
The FDA has signed off Landos Biopharma’s (NASDAQ: LABP) Investigational New Drug application for omilancor (BT-11) for the treatment of Eosinophilic Esophagitis (EoE). Landos expects to initiate patient dosing in the first half of 2022.
GlobeNewsWire
Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis
Tuesday Apr 06 2021 at 07:00
Third potential indication for omilancor (BT-11), a first-in-class candidate for the treatment of autoimmune diseases Third potential indication for omilancor (BT-11), a first-in-class candidate for the treatment of autoimmune diseases
Seeking Alpha
U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week
Monday Feb 08 2021 at 02:14
The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion market cap.
Barrons
A Busy Day for Biotech IPOs
Thursday Feb 04 2021 at 14:35
Three biotechs—Sana Biotechnology, Landos Biopharma, Sensei Biotherapeutics—and chemicals specialist Atotech made their public-market debut Thursday. Here’s how they fared.
GlobeNewsWire
Landos Biopharma Announces Pricing of Initial Public Offering
Wednesday Feb 03 2021 at 20:13
BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Landos Biopharma. All of the shares of the common stock are being offered by Landos Biopharma.
Landos Biopharma Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Landos Biopharma’s Altman Z-score is -2.71 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Landos Biopharma Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Landos Biopharma.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Landos Biopharma’s Income Quality of 0.9 is greater than its Industry Group of 0.69 (30.4% greater)
Landos Biopharma’s Income Quality of 0.9 is greater than its Major Industry Group of 0.71 (26.8% greater)
Landos Biopharma’s Income Quality of 0.9 is greater than its Sector of 0.75 (20.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Landos Biopharma’s Current Ratio of 15.35 is greater than its Industry Group of 4.76 (222.5% greater)
Landos Biopharma’s Current Ratio of 15.35 is greater than its Major Industry Group of 4.32 (255.3% greater)
Landos Biopharma’s Current Ratio of 15.35 is greater than its Sector of 2.6 (490.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.54 & -1.27)
Cannot compare a negative PE Ratio (-0.54 & -1.1)
Cannot compare a negative PE Ratio (-0.54 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Landos Biopharma’s PB Ratio of 0.27 is lower than its Industry Group of 1.34 (-79.9% lower)
Landos Biopharma’s PB Ratio of 0.27 is lower than its Major Industry Group of 1.4 (-80.7% lower)
Landos Biopharma’s PB Ratio of 0.27 is lower than its Sector of 1.62 (-83.3% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Landos Biopharma’s ROE of -0.49 is lower than its Industry Group of -0.44 (-11.4% lower)
Landos Biopharma’s ROE of -0.49 is lower than its Major Industry Group of -0.38 (-28.9% lower)
Landos Biopharma’s ROE of -0.49 is lower than its Sector of -0.03 (-1533.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Landos Biopharma’s ROCE of -0.58 is lower than its Industry Group of -0.42 (-38.1% lower)
Landos Biopharma’s ROCE of -0.58 is lower than its Major Industry Group of -0.37 (-56.8% lower)
Landos Biopharma’s ROCE of -0.58 is lower than its Sector of -0.04 (-1350.0% lower)
Derived from SEC.GOV filing dataopen_in_new